Selection and evolution of resistance to antimicrobial drugs

IUBMB Life

Volumn 66, Issue 8, 2014, Pages 521-529

  Hughes, Diarmaid ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

antibiotic; evolution; fitness; fluoroquinolone; resistance; rifampicin; sub MIC

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; DRUG DEVELOPMENT; EUROPE; EVOLUTION; GENETIC SELECTION; GENETICS; INAPPROPRIATE PRESCRIBING; MICROBIAL SENSITIVITY TEST; PROCEDURES; REPRODUCTIVE FITNESS; STATISTICS AND NUMERICAL DATA; TRENDS;

ANTI-INFECTIVE AGENTS; BIOLOGICAL EVOLUTION; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; EUROPE; GENETIC FITNESS; INAPPROPRIATE PRESCRIBING; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; SELECTION, GENETIC;

EID: 84930146645     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1278     Document Type: Review

References (60)

1. Amin, A. N., Cerceo E. A., Deitelzweig S. B., Pile J. C., Rosenberg, D. J., et al. (2014) The hospitalist perspective on treatment of community-acquired bacterial pneumonia. Postgrad. Med. 126: 18-29.
2. Thiem, U., Heppner, H. J., and, Pientka, L., (2011) Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging 28: 519-537.
3. Schlesinger, A., Paul, M., Gafter-Gvili, A., Rubinovitch, B., and, Leibovici, L., (2009) Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect. Dis. 9: 97-107.
4. Becker, J. U., Theodosis, C., Jacob, S. T., Wira, C. R., and, Groce, N. E., (2009) Surviving sepsis in low-income and middle-income countries: new directions for care and research. Lancet Infect. Dis. 9: 577-582.
5. Ilic, K., Jakovljevic, E., and, Skodric-Trifunovic, V., (2012) Social-economic factors and irrational antibiotic use as reasons for antibiotic resistance of bacteria causing common childhood infections in primary healthcare. Eur. J. Pediatrics 171: 767-777.
6. Nga do, T. T., Chuc, N. T., Hoa, N. P., Hoa, N. Q., Nguyen, N. T., et al. (2014) Antibiotic sales in rural and urban pharmacies in northern Vietnam: an observational study. BMC Pharmacol. Toxicol. 15: 6.
7. Holloway, K. A., Ivanovska, V., Wagner, A. K., Vialle-Valentin, C., and, Ross-Degnan, D., (2013) Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Trop. Med. Int. Health 18: 656-664.
8. Kotwani, A., Wattal, C., Joshi, P. C., and, Holloway, K., (2012) Irrational use of antibiotics and role of the pharmacist: an insight from a qualitative study in New Delhi, India. J. Clin. Pharm. Ther. 37: 308-312.
9. McCaughey, G., Gilpin, D., Elborn, J., and, Tunney, M. M., The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Exp. Rev. Respir. Med. 7: 385-96.
10. McGann, P., Courvalin, P., Snesrud, E., Clifford, R. J., Yoon, E. J., et al. (2014) Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. MBio 5: e00915.
11. Bryskier, A., ed. (2005) Antimicrobial Agents: Antibacterials and Antifungals, ASM Press, Washington, DC.
12. Sarmah, A. K., Meyer, M. T., and, Boxall, A. B., (2006) A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (Vas) in the environment. Chemosphere 65: 725-759.
13. Sukul, P., and, Spiteller, M., (2007) Fluoroquinolone antibiotics in the environment. Rev. Environ. Contam. Toxicol. 191: 131-162.
14. McCaughey, G., Diamond, P., Elborn, J. S., McKevitt, M., and, Tunney, M. M., (2013) Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PloS one 8: e69763.
15. Marvig, R. L., Johansen, H. K., Molin, S., and, Jelsbak, L., (2013) Genome analysis of a transmissible lineage of pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PloS Genet. 9: e1003741.
16. Matteelli, A., Roggi, A., and, Carvalho, A. C., (2014) Extensively drug-resistant tuberculosis: epidemiology and management. Clin. Epidemiol. 6: 111-118.
17. Meier, A., Heifets, L., Wallace, R. J. Jr., Zhang, Y., Brown, B. A., et al. (1996) Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174: 354-360.
18. Holmes, N. E., Ballard, S. A., Lam, M. M., Johnson, P. D., Grayson, M. L., et al. (2013) Genomic analysis of teicoplanin resistance emerging during treatment of vanB vancomycin-resistant Enterococcus faecium infections in solid organ transplant recipients including donor-derived cases. J. Antimicrob. Chemother. 68: 2134-2139.
19. Tenover, F. C., (2006) Mechanisms of antimicrobial resistance in bacteria. Am. J. Infect. Control 34 (Suppl 1): S3-S10; discussion S64-7S3.
20. Jacoby, G. A., (2005) Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41 (Suppl 2): S120-S126.
21. Versporten, A., Bolokhovets, G., Ghazaryan, L., Abilova, V., Pyshnik, G., et al. (2014) Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect. Dis. 14: 381-387.
22. Andersson, D. I., and, Hughes, D., (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8: 260-271.
23. Nagaev, I., Bjorkman, J., Andersson, D. I., and, Hughes, D., (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40: 433-439.
24. Marcusson, L. L., Frimodt-Moller, N., and, Hughes, D., (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PloS Pathog 5: e1000541.
25. Schrag, S. J., Perrot, V., and, Levin, B. R., (1997) Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. Biol. Sci. 264: 1287-1291.
26. Dahlberg, C., and, Chao, L., (2003) Amelioration of the cost of conjugative plasmid carriage in Eschericha coli K12. Genetics 165: 1641-1649.
27. Starikova, I., Al-Haroni, M., Werner, G., Roberts, A. P., Sorum, V., et al. (2013) Fitness costs of various mobile genetic elements in Enterococcus faecium and Enterococcus faecalis. J. Antimicrob. Chemother. 68: 2755-2765.
28. Andersson, D. I., and, Hughes, D., (2011) Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 35: 901-911.
29. McGowan, J. E. Jr,. (1986) Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect. Control 7: 573-576.
30. Mahamat, A., MacKenzie, F. M., Brooker, K., Monnet, D. L., Daures, J. P., et al. (2007) Impact of infection control interventions and antibiotic use on hospital MRSA: a multivariate interrupted time-series analysis. Int. J. Antimicrob. Agents 30: 169-176.
31. Aldeyab, M. A., Monnet, D. L., Lopez-Lozano, J. M., Hughes, C. M., Scott, M. G., et al. (2008) Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J. Antimicrob. Chemother. 62: 593-600.
32. Austin, D. J., and, Anderson, R. M., (1999) Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos. Trans. R Soc. Lond. B Biol. Sci. 354: 721-738.
33. Lipsitch, M., Bergstrom, C. T., and, Levin, B. R., (2000) The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc. Natl. Acad. Sci. USA 97: 1938-1943.
34. Bonten, M. J., Austin, D. J., and, Lipsitch, M., (2001) Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control. Clin Infect Dis 33: 1739-1746.
35. Enne, V. I., Livermore, D. M., Stephens, P., and, Hall, L. M., (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357: 1325-1328.
36. Seppälä, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H., et al. (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337: 441-446.
37. Kristinsson, K. G., (1997) Effect of antimicrobial use and other risk factors on antimicrobial resistance in Pneumococci. Microb. Drug Resist. 3: 117-123.
38. Sundqvist, M., Geli, P., Andersson, D. I., Sjolund-Karlsson, M., Runehagen, A., et al. (2009) Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J. Antimicrob. Chemother. 65: 350-360.
39. Bottger, E. C., Springer, B., Pletschette, M., and, Sander, P., (1998) Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 4: 1343-1344.
40. Pfister, P., Corti, N., Hobbie, S., Bruell, C., Zarivach, R., et al. (2005) 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A → G. Proc. Natl. Acad. Sci. USA 102: 5180-5185.
41. Sander, P., Springer, B., Prammananan, T., Sturmfels, A., Kappler, M., et al. (2002) Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 46: 1204-1211.
42. Johanson, U., Aevarsson, A., Liljas, A., and, D. Hughes, (1996) The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J. Mol. Biol. 258: 420-432.
43. Bjorkman, J., Hughes, D., and, Andersson, D. I., (1998) Virulence of antibiotic-resistant Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 95: 3949-3953.
44. Shcherbakov, D., Akbergenov, R., Matt, T., Sander, P., Andersson, D. I., et al. (2010) Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 77: 830-840.
45. Comas, I., Borrell, S., Roetzer, A., Rose, G., Malla, B., et al. (2012) Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44: 106-110.
46. Casali, N., Nikolayevskyy, V., Balabanova, Y., Ignatyeva, O., Kontsevaya, I., et al. (2012) Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res. 22: 735-745.
47. Brandis, G., Wrande, M., Liljas, L., and, Hughes, D., (2012) Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol. Microbiol. 85: 142-151.
48. Brandis, G., and, Hughes, D., (2013) Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J. Antimicrob. Chemother. 68: 2493-2497.
49. Pepperell, C. S., Casto, A. M., Kitchen, A., Granka, J. M., Cornejo, O. E., et al. (2013) The role of selection in shaping diversity of natural M. tuberculosis populations. PLoS Pathogens 9: e1003543.
50. Komp Lindgren, P., Karlsson, Å., and, Hughes, D., (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47: 3222-3232.
51. Nazir, H., Cao, S., Hasan, F., and, Hughes, D., (2011) Can phylogenetic type predict resistance development? J. Antimicrob. Chemother. 66: 778-787.
52. Drlica, K., and, Zhao, X., (2007) Mutant selection window hypothesis updated. Clin. Infect. Dis. 44: 681-688.
53. Baquero, F., and, Negri, M. C., (1997) Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays 19: 731-736.
54. Baquero, F., Negri, M. C., Morosini, M. I., and, Blazquez, J., (1998) Antibiotic-selective environments. Clin. Infect. Dis. 27 (Suppl 1): S5-S11.
55. Gullberg, E., Cao, S., Berg, O. G., Ilback, C., Sandegren, L., et al. (2011) Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathogens 7: e1002158.
56. Liu, A., Fong, A., Becket, E., Yuan, J., Tamae, C., et al. (2011) Selective advantage of resistant strains at trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics and genotoxic agents. Antimicrob. Agents Chemother. 55: 1204-1210.
57. Le-Minh, N., Khan, S. J., Drewes, J. E., and, Stuetz, R. M., (2010) Fate of antibiotics during municipal water recycling treatment processes. Water Res. 44: 4295-4323.
58. Michael, I., Rizzo, L., McArdell, C. S., Manaia, C. M., Merlin, C., et al. (2013) Urban wastewater treatment plants as hotspots for the release of antibiotics in the environment: a review. Water Res. 47: 957-995.
59. Manzetti, S., and, Ghisi, R., (2014) The environmental release and fate of antibiotics. Mar. Pollut. Bull. 79: 7-15.
60. Hughes, D., and, Karlen, A., (2014) Discovery and preclinical development of new antibiotics. Upsala J. Med. Sci. 119: 162-169.